Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
15/10/2025 13:03
Oct 15 (Reuters) - SK Bioscience Co Ltd 302440.KS: SK BIOSCIENCE FILES FOR FIRST-IN-HUMAN TRIAL OF UNIVERSAL CORONAVIRUS VACCINE (PAN-SARBECOVIRUS VACCINE) GBP511 PHASE 1/2 STUDY IN AUSTRALIA SK BIOSCIENCE CO LTD - TRIAL TO ENROLL 500 ADULTS IN AUSTRALIA, RESULTS BY 2028 SK BIOSCIENCE CO LTD - PHASE 1/2 STUDY TOPLINE RESULTS EXPECTED BY 2028 Source text: ID:nPn4STSzHa Further company coverage: 302440.KS
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine